Dr. Moshe Giladi currently serves as novocure Sr. Director of Pre-Clinical Research Department, Leading a team of trained experts of various fields: cancer, immunology, cell biology, mechanical and electrical engineering. Other responsibilities also include research collaboration with academic institutions. Dr. Giladi joined Novocure in 2005 at this time point he served as head of the NovoBiotic project at Novocure. Dr. Moshe Giladi holds an MSc, MBA and PhD from Tel Aviv University of Israel. 

Ezequiel Gleichgerrcht, MD, PhD, is a Clinical Instructor at the Medical University of South Carolina, where he previously completed post-doctoral research work in the Bonilha lab. He obtained his undergraduate degree summa cum laude in Neuroscience & Biology in Dickinson College (Carlisle, PA, USA). He later completed his medical degree at the University of Buenos Aires (Argentina). During his training, Gleichgerrcht conducted research in cognitive neurology and neuroscience at the Institute of Cognitive Neurology (INECO) in Buenos Aires, Argentina, with a strong focus on neuropsychiatric diseases involving the frontal lobes and a particular interest for affective and social processes in the brain.
 
Ezequiel Gleichgerrcht served as the Science Coordinator at the INECO Foundation, where he also directed the Social Neuroscience & Education research laboratory. He was the co-chair of the Institute of Neuroscience & Education in Argentina. Gleichgerrcht was an associate professor at Favaloro University (Argentina) and a guest lecturer in several universities across the Latin American region. 

Dr. Mark Hallett obtained his A.B. and M.D. at Harvard University, had his internship in Medicine at the Peter Bent Brigham Hospital and his Neurology training at Massachusetts General Hospital. He had fellowships in neurophysiology at the NIH and in the Department of Neurology, Institute of Psychiatry in London, where he worked with C. David Marsden. Before coming to NIH in 1984, Dr. Hallett was the Chief of the Clinical Neurophysiology Laboratory at the Brigham and Women's Hospital in Boston and progressed to Associate Professor of Neurology at Harvard Medical School. He is currently Chief of the Medical Neurology Branch and Chief of its Human Motor Control Section. He is now Past-President of the International Federation of Clinical Neurophysiology. He has been President of the International Parkinson and Movement Disorder Society and Vice-President of the American Academy of Neurology. He served as Editor in Chief of Clinical Neurophysiology. Among many awards, in 2012 he became an Honorary Member of the American Neurological Association, and in 2014 won the Lifetime Achievement Award of the American Association of Neuromuscular and Electrodiagnostic Medicine. In 2017 he received the degree of Doctor of Medicine Honoris Causa from the University of Hamburg, and in 2018 was made an Honorary Member of the European Academy of Neurology. His research activities focus on the physiology of human voluntary movement and its pathophysiology in disordered voluntary movement and involuntary movement. 

Thomas Hartung, MD, PhD, is the Doerenkamp-Zbinden-Chair for Evidence-based Toxicology with a joint appointment for Molecular Microbiology and Immunology at Johns Hopkins Bloomberg School of Public Health, Baltimore. He holds a joint appointment as Professor for Pharmacology and Toxicology at University of Konstanz, Germany; he also is Director of Centers for Alternatives to Animal Testing (CAAT, http://caat.jhsph.edu) of both universities with the portal AltWeb (http://altweb.jhsph.edu). CAAT hosts the secretariat of the Evidence-based Toxicology Collaboration (http://www.ebtox.com), the Good Read-Across Practice Collaboration, the Good Cell Culture Practice Collaboration, the Green Toxicology Collaboration, and the Industry Refinement Working Group. As PI, he heads the Human Toxome project (http://humantoxome.com), funded as an NIH Transformative Research Grant. He is the former Head of the European Commission’s Center for the Validation of Alternative Methods (ECVAM), Ispra, Italy, and has authored more than 490 scientific publications.

Dietrich Haubenberger received his medical degree and training as a neurologist at the Medical University of Vienna, Austria, followed by a tenure track position to become Associate Professor of Neurology in 2014. Dr. Haubenberger’s research focuses on the area of movement disorders, where he is an expert in tremor disorders. He published in the field of clinical genetics, neurophysiology, outcome measures research, as well as clinical trials. From 2008-2011, Dr. Haubenberger completed a clinical research fellowship at the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health conducting IND-regulated clinical trials in patients with Essential Tremor. Dr. Haubenberger returned to NINDS in 2014 as Assistant Clinical Director for Clinical Research and built up and directed the NINDS Clinical Trials Unit. In 2019, Dr. Haubenberger transitioned into a role as Medical Director for Early Clinical Development at Neurocrine Biosciences.  He is a member of the Board of Directors of the American Society for Experimental Neurotherapeutics (ASENT). 

Dr. Jinnah received a joint B.S. in Psychology & Zoology from Duke University, focusing on the biological basis of behavior in 1985. With support from the Medical Scientist Training Program at the University of California in San Diego, he completed M.D. and Ph.D. degrees in 1992. After finishing his Neurology Residency at Johns Hopkins University in 1996, he joined the faculty there and focused on clinical and research questions in Movement Disorders. Dr. Jinnah joined the faculty at Emory University in 2008, where currently he is a Professor in the Departments of Neurology and Human Genetics. 

Dr. Aditya Joshi earned his MD at the University of Pittsburgh School of Medicine, after receiving an S.B. in Brain and Cognitive Science and an S.B. in Physics from the Massachusetts Institute of Technology. He completed residency in neurology, fellowship in epilepsy, and fellowship in clinical neurophysiology (focusing on intraoperative monitoring) at Stanford Hospital and Clinics and is now an Assistant Professor of Clinical Neurology at the University of Pennsylvania. While at Stanford, Dr. Joshi participated in the Stanford Biodesign Innovation course, and was a member of the first Short Course in Adaptive Neurotechnologies held by the NIH-funded National Center for Adaptive Neurotechnologies. He is currently a member of the ASENT Annual Meeting Program Committee. He is very interested in the application of medical devices that utilize electromagnetic fields to interact with the body for the diagnosis and treatment of medically refractory epilepsy and other neurological disorders. 

Bennett Lavenstein, M.D., serves as the Movement Disorders Program Director at Children’s National Hospital. He is a professor of neurology and pediatrics at George Washington University School of Medicine & Health Science. Dr. Lavenstein's clinical interests include movement disorders and pharmacology; his research interests include deep brain stimulation, as well as therapeutics in movement disorders. He is a member of the ASENT Board of Directors.  

Emily M. Lee, PhD, is a Staff Scientist in the 3D Tissue Bioprinting Lab at the National Center for Advancing Translational Sciences (NCATS), NIH. Emily received her PhD from Florida State University in Dr. Hengli Tang's lab in early 2018, where her work primarily focused on the molecular mechanisms for pathogenesis of hepatitis C virus (HCV) and Zika virus (ZIKV).  

Dr. Chris Lee-Messer is a Clinical Assistant Professor in Neurology at Stanford University. Dr. Lee-Messer received his B.A. at Harvard University and M.D. and Ph.D. at Washington University in St. Louis. He completed an internship in pediatrics at the University of California, San Francisco, before completing residency in child neurology at Stanford and Lucile Packard Children's Hospital. He has also completed an epilepsy fellowship at Stanford. 

Dr. Lee-Messer's research has focused on the role of neuronal microcircuits in information processing and development, and he has conducted postdoctoral research in optogenetics in the laboratory of Professor Karl Deisseroth in the departments of Bioengineering and Psychiatry at Stanford.   He now works as a member of the pediatric epilepsy and general child neurology groups.  

David R. Liu is the Richard Merkin Professor, director of the Merkin Institute of Transformative Technologies in Healthcare, and vice chair of the faculty at the Broad Institute of Harvard and MIT; a professor of chemistry and chemical biology at Harvard University and a Howard Hughes Medical Institute (HHMI) investigator. Liu’s research integrates chemistry and evolution to illuminate biology and enable next-generation therapeutics. His major research interests include the engineering, evolution, and in vivo delivery of genome editing proteins such as base editors to study and treat genetic diseases; the evolution of proteins with novel therapeutic potential using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic small molecules and synthetic polymers using DNA-templated organic synthesis and DNA-encoded libraries. Base editing (named one of four 2017 Breakthrough of the Year finalists by Science), prime editing, PACE, and DNA-templated synthesis are four examples of technologies pioneered in his laboratory. 

Liu graduated first in his class at Harvard in 1994. He performed organic and bioorganic chemistry research on sterol biosynthesis under Professor E. J. Corey’s guidance as an undergraduate. During his Ph.D. research with Professor Peter Schultz at U. C. Berkeley, Liu initiated the first general effort to expand the genetic code in living cells. He earned his Ph.D. in 1999 and became assistant professor of chemistry and chemical biology at Harvard University in the same year. He was promoted to associate professor in 2003 and to full professor in 2005. Liu became a Howard Hughes Medical Institute investigator in 2005 and joined the JASONs, academic science advisors to the U.S. government, in 2009. 

Liu has earned several university-wide distinctions for teaching at Harvard, including the Joseph R. Levenson Memorial Teaching Prize, the Roslyn Abramson Award, and a Harvard College Professorship. Liu has published more than 195 papers and is the inventor on more than 75 issued U.S. patents. His research accomplishments have earned distinctions including the Ronald Breslow Award for Biomimetic Chemistry, the American Chemical Society David Perlman Award, ACS Chemical Biology Award, the American Chemical Society Pure Chemistry Award, the Arthur Cope Young Scholar Award, the NIH Marshall Nirenberg Lecturer, and awards from the Sloan Foundation, Beckman Foundation, NSF CAREER Program, and Searle Scholars Program. In 2016 and 2019 he was named one of the Top 20 Translational Researchers in the world by Nature Biotechnology, and in 2017 was named one of Nature’s 10 researchers in world and to the Foreign Policy Leading Global Thinkers. In 2020 he was elected to the National Academy of Medicine and was named as a Fellow of the American Association for the Advancement of Science (AAAS). He is the scientific founder or co-founder of several biotechnology and therapeutics companies, including Editas Medicine, Pairwise Plants, Exo Therapeutics, Beam Therapeutics, and Prime Medicine. 

Eliezer Masliah, M.D., joined the National Institute on Aging (NIA) as Director of the Division of Neuroscience in the summer of 2016. Dr. Masliah received his M.D. from the National Autonomous University of Mexico in 1982. He completed a postgraduate residency training in pathology at the National Institutes of Health in Mexico City in 1986. Following a fellowship in neuropathology and neurodegenerative disorders at the University of California, San Diego (UCSD), before joining NIA he held joint appointments as tenured track Professor at the Departments of Neurosciences and Pathology and as Director of the Autopsy Service at UCSD-Medical Center. 

As head of UCSD’s Experimental Neuropathology Laboratory, he investigated synaptic damage in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and AIDS-related dementia. His laboratory was involved with the discovery of alpha-synuclein and developed novel models of neurodegeneration, as well as new gene therapies, small molecules, and experimental immunotherapies for Alzheimer's disease and Parkinson's disease. Four of the experimental therapeutic approaches developed at his laboratory targeting alpha-synuclein have now passed Phase I clinical trials. He also directed the neuropathology core of the NIA-supported Shiley-Marcos Alzheimer’s Disease Research Center. 

A prolific author with approximately 800 original research articles, 70 book chapters and dozens of patents, Dr. Masliah has familiarity with NIA as a past member of the NIA National Advisory Council on Aging, the NIA Neuroscience of Aging Study Section, and the Cellular and Molecular Biology of Neurodegeneration Study Section. He has also served as an advisor in expert panels to revise the criteria for the neuropathological diagnosis of Alzheimer’s disease organized by NIA and the Alzheimer’s Association, at scientific meetings and workshops to advise on the use of preclinical models for Alzheimer’s disease, and at a series of summits hosted by the National Institutes of Health (NIH) on Alzheimer’s and related dementias. Dr. Masliah served as a member of the Scientific Advisory Board of the Alzheimer’s Association from 2010-2016. 

As Director of the Division of Neuroscience at NIA, Dr. Masliah is responsible for managing the portfolios and providing leadership on NIH-sponsored programs dedicated to better understanding brain aging and Alzheimer’s disease. The division plays a key role in developing the implementation research milestones targeting the ultimate goal of the National Plan to Address Alzheimer’s Disease, which calls for the nation to identify effective ways to treat or prevent Alzheimer’s disease and related dementias by 2025. Dr. Masliah also participates in the NIA Intramural Research Program as an investigator in the Laboratory of Neurogenetics. 

As cognitive neurologist Dr. McDade has focused his activities on the evaluation of those with dementia syndromes and on developing a clinical research program that focuses on identifying critical interactions between vascular disease and neurodegenerative pathologies. He is an Associate Professor of Neurology at Washington University School of Medicine in St. Louis. Dr. McDade’s research focus is on the use of neuroimaging and cerebrospinal fluid techniques to study the early markers of dementia as it relates to familial dementia syndromes, dementia prevention and clinical trials in dementia. 
 
Dr. McDade is actively involved in the Dominantly Inherited Alzheimer Network and serves as the local PI for both the observational and treatment trial.  

Dr. Nina Mezu-Nwaba is a Captain and a pharmacist with the United States Public Health Service.  Currently, she serves as the Deputy Office Director for Office of Neurological and Physical Medicine Devices, Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration (FDA). Previously, she was the Assistant Director (Acting) for Plastic Surgery Implant Devices Team in CDRH. She has over 20 years of clinical, scientific and regulatory experience in both Center for Drug Evaluation and Research and CDRH.

CAPT Mezu-Nwaba earned her Doctor of Pharmacy from the University of Maryland at Baltimore, her Masters in Biomedical Science from Georgetown University, and her Masters in Public Health from the Johns Hopkins Bloomberg School of Public Health. 

She aims to bridge the gaps in health disparities through various volunteer and advocacy work. As an officer, she has participated in deployments in support of COVID-19 Pandemic, Hurricane Katrina and Maria, Anthrax and 9/11 Response Missions. CAPT Mezu-Nwaba is the Lead Coordinator for the Opioid Overdose Response and Naloxone training at the FDA. Additionally, she works with various State Health Departments’ opioid and health prevention teams. She is a passionate health educator, with invited lectures, locally and internationally, on numerous topics pertaining to public health and regulatory policy. As the past President of the Pikesville Rotary Club, she organized the first community wide opioid and naloxone training for the club. During her spare time, CAPT Mezu-Nwaba enjoys cooking, traveling abroad, volunteering and spending time with family.

Dr. Lloyd Mitchell received his MD degree from the University of Maryland at Baltimore. His post-graduate training includes an internship in Internal Medicine at the University of South Florida, residency in clinical pathology at the George Washington University and a fellowship in molecular biology at the NIH. Dr. Mitchell has founded 2 biotechnology companies based on his inventions. Currently, he is CEO and Chief Scientific Officer of RetroTherapy, the only company to receive a grant from the Maryland Stem Cell Fund. He is also an Associate Professor at Howard University School of Medicine. Dr. Mitchell has 6 issued US patents along with over 15 additional published US applications and has authored 27 publications. He is the sole inventor of spliceosome mediated RNA trans-splicing, the most effective means to reprogram/re-write gene expression in vivo.